Logo image of ADXN

ADDEX THERAPEUTICS LTD (ADXN) Stock Overview

USA - NASDAQ:ADXN - US00654J2069 - ADR

9.6 USD
-0.25 (-2.54%)
Last: 10/24/2025, 8:08:01 PM

ADXN Key Statistics, Chart & Performance

Key Statistics
Market Cap10.26M
Revenue(TTM)564.10K
Net Income(TTM)-5653200
Shares1.07M
Float501.83K
52 Week High12.05
52 Week Low6.51
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-6.85
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO2007-05-22
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ADXN short term performance overview.The bars show the price performance of ADXN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

ADXN long term performance overview.The bars show the price performance of ADXN in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40

The current stock price of ADXN is 9.6 USD. In the past month the price increased by 6.25%. In the past year, price decreased by -6.43%.

ADDEX THERAPEUTICS LTD / ADXN Daily stock chart

ADXN Latest News, Press Relases and Analysis

ADXN Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 51.11 781.26B
JNJ JOHNSON & JOHNSON 18.34 458.55B
AZN ASTRAZENECA PLC-SPONS ADR 18.76 258.24B
NVS NOVARTIS AG-SPONSORED ADR 14.73 252.36B
NVO NOVO-NORDISK A/S-SPONS ADR 13.65 235.32B
MRK MERCK & CO. INC. 11.36 218.53B
PFE PFIZER INC 7.3 140.77B
SNY SANOFI-ADR 11.74 125.85B
GSK GSK PLC-SPON ADR 9.65 86.97B
BMY BRISTOL-MYERS SQUIBB CO 6.51 89.21B
ZTS ZOETIS INC 23.46 64.68B
TAK TAKEDA PHARMACEUTIC-SP ADR 50.04 44.25B

About ADXN

Company Profile

ADXN logo image Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 2 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Company Info

ADDEX THERAPEUTICS LTD

Chemin des Mines, 9

Plan-les-Ouates GENEVE CH-1202 CH

CEO: Tim Dyer

Employees: 2

ADXN Company Website

ADXN Investor Relations

Phone: 41228841555

ADDEX THERAPEUTICS LTD / ADXN FAQ

What does ADXN do?

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 2 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.


Can you provide the latest stock price for ADDEX THERAPEUTICS LTD?

The current stock price of ADXN is 9.6 USD. The price decreased by -2.54% in the last trading session.


Does ADXN stock pay dividends?

ADXN does not pay a dividend.


How is the ChartMill rating for ADDEX THERAPEUTICS LTD?

ADXN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


On which exchange is ADXN stock listed?

ADXN stock is listed on the Nasdaq exchange.


Would investing in ADDEX THERAPEUTICS LTD be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADXN.


ADXN Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ADXN. When comparing the yearly performance of all stocks, ADXN turns out to be only a medium performer in the overall market: it outperformed 40.65% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ADXN Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ADXN. ADXN has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ADXN Financial Highlights

Over the last trailing twelve months ADXN reported a non-GAAP Earnings per Share(EPS) of -6.85. The EPS decreased by -276.06% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -66.46%
ROE -78.38%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-115%
Sales Q2Q%-68.43%
EPS 1Y (TTM)-276.06%
Revenue 1Y (TTM)-34.65%

ADXN Forecast & Estimates

9 analysts have analysed ADXN and the average price target is 7.61 USD. This implies a price decrease of -20.71% is expected in the next year compared to the current price of 9.6.

For the next year, analysts expect an EPS growth of -1500% and a revenue growth -21.42% for ADXN


Analysts
Analysts40
Price Target7.61 (-20.73%)
EPS Next Y-1500%
Revenue Next Year-21.42%

ADXN Ownership

Ownership
Inst Owners1.32%
Ins Owners7.07%
Short Float %0.82%
Short Ratio0.12